Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BCRX
BCRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCRX News
Rising Oil Prices and Middle East Tensions Impact Market Sentiment
Mar 24 2026
stocktwits
BioCryst Shares Surge in After-Hours Trading Amid Speculation of Major Pharma Interest — Retail Sentiment Reaches Highest Level Since 2026
Mar 24 2026
stocktwits
BioCryst Pharmaceuticals (BCRX) Shares Surge 15% Amid Takeover Speculation
Mar 16 2026
seekingalpha
BioCryst Pharmaceuticals Acquires Astria, Enhancing Market Position
Feb 27 2026
Yahoo Finance
BioCryst Pharmaceuticals Reports Strong Q4 2025 Earnings
Feb 26 2026
seekingalpha
BioCryst Pharmaceuticals Q4 Earnings Exceed Expectations
Feb 26 2026
seekingalpha
BioCryst Pharmaceuticals Q4 Earnings Preview
Feb 25 2026
seekingalpha
BioCryst Pharmaceuticals Faces Dismal Outlook
Feb 07 2026
Yahoo Finance
Astria Therapeutics to be Sold to BioCryst for $8.55 per Share
Jan 07 2026
PRnewswire
BioCryst Grants 18,300 RSUs to New Employee as Inducement
Jan 06 2026
Globenewswire
BioCryst to Present at J.P. Morgan Healthcare Conference on January 12, 2026
Jan 06 2026
Globenewswire
BioCryst Receives FDA Approval for Oral Medication to Treat Rare Swelling Disorder in Children
Dec 12 2025
Benzinga
BioCryst Receives FDA Approval for ORLADEYO Oral Therapy for Pediatric HAE Patients
Dec 12 2025
Globenewswire
BioCryst Receives FDA Approval for ORLADEYO Oral Therapy for Pediatric HAE Patients
Dec 12 2025
Newsfilter
FDA Grants Approval for Orladeyo Oral Pellets for Pediatric Patients with Hereditary Angioedema
Dec 12 2025
NASDAQ.COM
BioCryst's Orladeyo Oral Pellets Approved by FDA for HAE Patients Aged 2 to Under 12
Dec 12 2025
NASDAQ.COM
Show More News
